Teva to pay $315 million to settle Medicaid pricing lawsuits
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries and several of its subsidiaries in the US have reached a settlement in principle to resolve certain lawsuits related to Medicaid reimbursement. The company has set aside $315 million to cover one settlement and a reserve for remaining US drug pricing lawsuits to which it is a party.